Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KRYS NASDAQ:NUVL NASDAQ:QURE NYSE:RDY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$335.19+2.3%$333.77$130.50▼$382.54$9.88B0.5585,251 shs520,339 shsNUVLNuvalent$123.96$115.86$71.13▼$123.99$9.79B1.141.93 million shsN/AQUREuniQure$38.97-1.2%$35.94$8.73▼$71.50$2.46B0.91.42 million shs1.35 million shsRDYDr. Reddy's Laboratories$11.78-0.2%$13.49$11.36▼$15.67$9.84B0.252.98 million shs3.23 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech0.00%-5.54%-6.87%+23.00%+118.72%NUVLNuvalent0.00%0.00%+0.35%+18.62%+54.03%QUREuniQure0.00%-3.18%-20.63%+116.14%+153.38%RDYDr. Reddy's Laboratories0.00%-6.81%-22.77%-13.86%-19.60%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKRYSKrystal Biotech$335.19+2.3%$333.77$130.50▼$382.54$9.88B0.5585,251 shs520,339 shsNUVLNuvalent$123.96$115.86$71.13▼$123.99$9.79B1.141.93 million shsN/AQUREuniQure$38.97-1.2%$35.94$8.73▼$71.50$2.46B0.91.42 million shs1.35 million shsRDYDr. Reddy's Laboratories$11.78-0.2%$13.49$11.36▼$15.67$9.84B0.252.98 million shs3.23 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKRYSKrystal Biotech0.00%-5.54%-6.87%+23.00%+118.72%NUVLNuvalent0.00%0.00%+0.35%+18.62%+54.03%QUREuniQure0.00%-3.18%-20.63%+116.14%+153.38%RDYDr. Reddy's Laboratories0.00%-6.81%-22.77%-13.86%-19.60%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKRYSKrystal Biotech 2.83Moderate Buy$360.677.60% UpsideNUVLNuvalent 2.15Hold$127.733.04% UpsideQUREuniQure 2.65Moderate Buy$64.1764.66% UpsideRDYDr. Reddy's Laboratories 1.67ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest QURE, RDY, NUVL, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026RDYDr. Reddy's Laboratories Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)7/14/2026KRYSKrystal Biotech Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$364.00 ➝ $396.007/13/2026KRYSKrystal Biotech Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$474.007/1/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)6/29/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $80.006/26/2026QUREuniQure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/25/2026QUREuniQure MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $68.006/24/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$172.00 ➝ $124.006/18/2026KRYSKrystal Biotech TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$306.00 ➝ $403.006/18/2026QUREuniQure Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$35.00 ➝ $65.006/18/2026QUREuniQure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKRYSKrystal Biotech$389.13M25.39$7.29 per share45.98$42.06 per share7.97NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/AQUREuniQure$16.10M152.66N/AN/A$3.19 per share12.22RDYDr. Reddy's Laboratories$3.58B2.75$0.85 per share13.92$4.90 per share2.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKRYSKrystal Biotech$204.83M$7.4844.8136.04N/A53.92%19.25%17.62%8/3/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)QUREuniQure-$198.97M-$3.48N/AN/AN/A-1,154.42%-145.81%-27.15%7/29/2026 (Estimated)RDYDr. Reddy's Laboratories$456M$0.4426.7618.992.1710.15%9.49%6.32%N/ALatest QURE, RDY, NUVL, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026NUVLNuvalent-$1.44N/AN/AN/A$0.25 millionN/A8/3/2026Q2 2026KRYSKrystal Biotech$1.70N/AN/AN/A$121.83 millionN/A7/29/2026Q2 2026QUREuniQure-$0.8223N/AN/AN/A$5.45 millionN/A7/21/2026Q1 26/27RDYDr. Reddy's Laboratories$0.0918$0.06-$0.0318$0.06$850.56 million$850.26 million5/12/2026Q4 25/26RDYDr. Reddy's Laboratories$0.09$0.06-$0.03-$0.03$886.58 million$852.55 million5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/5/2026Q1 2026QUREuniQure-$0.88-$0.85+$0.03-$0.85$5.21 million$3.56 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKRYSKrystal BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ARDYDr. Reddy's Laboratories$0.070.59%+6.96%15.91%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKRYSKrystal BiotechN/A9.469.06NUVLNuvalentN/A16.1416.14QUREuniQure0.3310.4010.40RDYDr. Reddy's Laboratories0.031.901.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKRYSKrystal Biotech86.29%NUVLNuvalent97.26%QUREuniQure78.83%RDYDr. Reddy's Laboratories3.85%Insider OwnershipCompanyInsider OwnershipKRYSKrystal Biotech13.10%NUVLNuvalent5.02%QUREuniQure4.65%RDYDr. Reddy's Laboratories2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionableQUREuniQure50063.07 million60.13 millionOptionableRDYDr. Reddy's Laboratories27,527834.67 million817.97 millionOptionableQURE, RDY, NUVL, and KRYS HeadlinesRecent News About These CompaniesRenaissance Technologies LLC Sells 395,400 Shares of Dr. Reddy's Laboratories Ltd $RDYJuly 26 at 5:43 AM | marketbeat.comWall Street Zen Downgrades Dr. Reddy's Laboratories (NYSE:RDY) to SellJuly 25 at 1:37 AM | americanbankingnews.comDr. Reddy's Laboratories (NYSE:RDY) Downgraded by Wall Street Zen to SellJuly 25 at 1:35 AM | marketbeat.comDr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)July 24 at 5:06 PM | prnewswire.comU.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEOJuly 24 at 3:00 AM | youtube.comYU.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warnsJuly 23 at 10:24 PM | cnbc.comDr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock DownJuly 23 at 11:41 AM | zacks.comWhy Dr. Reddy's sank: Profit plunge, semaglutide setback and Trump's tariff threatJuly 22, 2026 | msn.comDr. Reddy's Laboratories Limited (RDY) Q1 2027 Earnings Call TranscriptJuly 22, 2026 | seekingalpha.comDoctor Reddy’s: Fiscal Q1 Earnings SnapshotJuly 22, 2026 | wtop.comWDr. Reddy's falls after Q1 results amid Trump’s tariff threatJuly 22, 2026 | seekingalpha.comDr. Reddy's Laboratories Q1 Earnings Call HighlightsJuly 22, 2026 | marketbeat.comDr. Reddy's Laboratories (NYSE:RDY) Issues Quarterly Earnings ResultsJuly 22, 2026 | marketbeat.comDr. Reddy's Laboratories (NYSE:RDY) Sets New 12-Month Low - Time to Sell?July 22, 2026 | marketbeat.comIndian drugmaker Dr Reddy's posts quarterly profit slumpJuly 22, 2026 | reuters.comDr. Reddy's Q1 earnings previewJuly 21, 2026 | msn.comDr. Reddy's Laboratories Ltd $RDY Holdings Lifted by Bessemer Group Inc.July 19, 2026 | marketbeat.comDr. Reddy's Laboratories (RDY) to Post Quarterly Earnings on WednesdayJuly 15, 2026 | americanbankingnews.comDr. Reddy's Laboratories (RDY) Projected to Release Quarterly Earnings on WednesdayJuly 15, 2026 | marketbeat.comHsbc Holdings PLC Sells 111,151 Shares of Dr. Reddy's Laboratories Ltd $RDYJuly 14, 2026 | marketbeat.comDr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall RiskJuly 12, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQURE, RDY, NUVL, and KRYS Company DescriptionsKrystal Biotech NASDAQ:KRYS$335.19 +7.69 (+2.35%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$339.01 +3.82 (+1.14%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nuvalent NASDAQ:NUVL$123.96 0.00 (0.00%) As of 07/16/2026Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.uniQure NASDAQ:QURE$38.97 -0.46 (-1.17%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$38.45 -0.52 (-1.33%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Dr. Reddy's Laboratories NYSE:RDY$11.78 -0.03 (-0.21%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$11.80 +0.03 (+0.25%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
